Sai Life Sciences · NSE: SAILIFE · BSE: 544306
Q3 FY25 results · Oct–Dec 2024
Sai Life Sciences reported revenue from operations of ₹439.78 crore and net profit of ₹53.85 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 439.78 | — | — | — | — |
| Other income | 9.12 | — | — | — | — |
| Total income | 448.89 | — | — | — | — |
| Profit before tax | 71.65 | — | — | — | — |
| Net profit for the period | 53.85 | — | — | — | — |
| EPS, basic (₹) | 2.89 | — | — | — | — |
| Net margin (%) | 12.2 | — | — |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 428.60 | — | — | — | — |
| Other income | 9.45 | — | — | — | — |
| Total income | 438.05 | — | — | — | — |
| Profit before tax | 67.91 | — | — | — | — |
| Net profit for the period | 51.06 | — | — | — | — |
| EPS, basic (₹) | 2.74 | — | — | — | — |
| Net margin (%) | 11.9 | — | — |
Consolidated
- Filed with BSE
- 07 Feb 2025, 16:03 IST
- Board meeting
- 06 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Feb 2025, 16:03 IST
- Board meeting
- 06 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE